Since TRPC4 is expressed in human DRG tissue [145] and TRPC4/5 has entered clinical trials for the treatment of central nervous system disorders, it is possible that TRPC4 antagonists may soon be useful in migraine treatment. This evidence concerns the gene TRPC4 and central nervous system disorder.